Mepolizumab response
MEPO trials were completed by 93.6%, (58/62) patients, while 4.8%, (3/62) withdrew due to adverse effects and 1.6%, (1/62) withdrew due to logistical reasons. MEPO (Figure 1) significantly improved symptom control [Mean(SD), ACQ6 baseline: 2.71(1.26) vs 1.95(1.64) at end-of-trial, P<0.001], AQLQ [Mean(SD), baseline: 4.33(1.27) to 5.41(1.35) at the end-of-trial, P<0.001] and total HADS [Median(IQR), baseline: 9.5(10) to 6(9.5) at end-of-trial, P=0.012]. Furthermore, MEPO (Figure 1) significantly reduced exacerbations [Median(IQR), baseline: 4(3) vs 2(3) at the end-of-trial, P<0.001], AHE [Median(IQR), baseline: 0(1) to 0(0) at the end-of-trial, P=0.006], PBE (cells/μL) [Median(IQR), baseline: 500(350) to 100(100) at end-of-trial, P<0.001), mOCS dose [Median(IQR), baseline: 10(10) to 5(7) at end-of-trial, P<0.001], and mOCS dependency [Baseline: 70.7%,(41/58); end-of-trial: 56.1% ,(32/57), P=0.008]. However, it did not significantly improve Clinic FEV1%, FENO nor the proportion of patients with multiple AHE.